163 related articles for article (PubMed ID: 22127347)
1. Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
Kaneko S; Kaneko M; Fukushima T
Int J Clin Oncol; 2013 Feb; 18(1):116-25. PubMed ID: 22127347
[TBL] [Abstract][Full Text] [Related]
2. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Kaneko M; Kaneko S; Suzuki K
Cancer Sci; 2009 Nov; 100(11):2193-201. PubMed ID: 19673886
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
Kaneko S; Ishibashi M; Kaneko M
Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Trifan OC; Durham WF; Salazar VS; Horton J; Levine BD; Zweifel BS; Davis TW; Masferrer JL
Cancer Res; 2002 Oct; 62(20):5778-84. PubMed ID: 12384538
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
[TBL] [Abstract][Full Text] [Related]
6. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Zhao Y; Hao Y; Ji H; Fang Y; Guo Y; Sha W; Zhou Y; Pang X; Southerland WM; Califano JA; Gu X
Cancer Prev Res (Phila); 2010 Jun; 3(6):787-96. PubMed ID: 20501859
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Pyrko P; Soriano N; Kardosh A; Liu YT; Uddin J; Petasis NA; Hofman FM; Chen CS; Chen TC; Schönthal AH
Mol Cancer; 2006 May; 5():19. PubMed ID: 16707021
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Villalona-Calero M; Schaaf L; Phillips G; Otterson G; Panico K; Duan W; Kleiber B; Shah M; Young D; Wu WH; Kuhn J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):23-33. PubMed ID: 16685529
[TBL] [Abstract][Full Text] [Related]
15. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
Komuro H; Li P; Tsuchida Y; Yokomori K; Nakajima K; Aoyama T; Kaneko M; Kaneda N
Med Pediatr Oncol; 1994; 23(6):487-92. PubMed ID: 7935175
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
18. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
[TBL] [Abstract][Full Text] [Related]
19. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Dickens DS; Cripe TP
J Pediatr Hematol Oncol; 2003 Sep; 25(9):709-14. PubMed ID: 12972806
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
Kolb EA; Houghton PJ; Kurmasheva RT; Mosse YP; Maris JM; Erickson SW; Guo Y; Teicher BA; Smith MA; Gorlick R
Pediatr Blood Cancer; 2020 May; 67(5):e28098. PubMed ID: 31975571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
